Nature Reviews' clinical content is written by internationally renowned clinical academics and researchers and targeted towards readers in the medical sciences, from postgraduate level upwards. While intended to be read by practicing doctors, researchers and academics within a specialty, we aim to make all our articles accessible to readers working in any medical discipline. In-depth Reviews present authoritative, up-to-date information on a topic, placing it in the context of a field's history and development. Topical discussion and opinions are proffered in Perspectives and News & Views articles, and in the Research Highlights section we filter primary research from a range of specialty and general medical journals.
《自然评论》的临床内容由国际知名的临床学者和研究人员撰写，面向医学科学领域的读者，从研究生水平向上。虽然我们的目标是由执业医生，研究人员和学术界的专业阅读，我们的目标是使我们所有的文章，读者在任何医学学科的工作。深入评论提供关于某个主题的权威、最新信息，将其置于某个领域的历史和发展背景下。主题讨论和观点在观点和新闻与观点文章中提供，在研究亮点部分，我们从一系列专业和综合医学期刊中筛选主要研究。
Liquid biopsy and minimal residual disease — latest advances and implications for cure
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0187-3
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0173-9
Vessel co-option in cancer
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0181-9
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0267-4
Biomarker-guided therapy for colorectal cancer: strength in complexity
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0241-1
Towards individualized therapy for metastatic renal cell carcinoma
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0209-1
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0281-6
Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0204-6
The emerging role of epigenetic therapeutics in immuno-oncology
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0266-5
Emerging epigenetic-modulating therapies in lymphoma
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0190-8
Genetic alterations and their clinical implications in DLBCL
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0225-1
Integrated molecular and clinical staging defines the spectrum of metastatic cancer
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0220-6
Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0272-7
Phase I trials as valid therapeutic options for patients with cancer
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0262-9
Advances in patient care through increasingly individualized therapy
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-018-0156-2
Therapeutic implications of germline genetic findings in cancer
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0179-3
A reality check of the accelerated approval of immune-checkpoint inhibitors
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0260-y
Two new agents target KRAS G12C
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0304-3
Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0285-2
TMB is linked with prognosis
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0206-4
BRAF+MEKi and ICI triplets show promise in melanoma
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0247-8
Brain metastases respond to neratinib plus capecitabine
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0207-3
WEE1 kinase inhibitor shows promise
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0270-9
Lorlatinib in ROS1-positive NSCLC
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0301-6
Microenvironment plasticity confers cetuximab resistance
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0259-4
Registration studies — when should patients be deemed ineligible for aggressive therapy?
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0180-x
Truly personalized therapy — an end to the era of one size fits all
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-018-0165-1
Chemotherapy as a TONIC to invigorate PD-1 inhibition in TNBC
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0232-2
Assembling the brain trust: the multidisciplinary imperative in neuro-oncology
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0235-z
Imatinib and the long tail of targeted drug development
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0287-0
Anti-BCMA CAR T cells for MM
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0229-x
CSF DNA provides a snapshot of the glioma genome
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0178-4
Pembrolizumab improves OS across PD-L1 subgroups
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0213-5
ECHELON-2 — brentuximab raises PTCL outcomes to new levels
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-018-0163-3
MILD trial, strong confirmation of lung cancer screening efficacy
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0231-3
Sequence of AR inhibitors affects outcome
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0307-0
Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0255-8
Healthier bones and less recurrence with denosumab
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0197-1
ALCYONE — lighting the way for quadruplet therapy of NDMM
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0321-2
Towards risk-stratified induction regimens
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0168-6
From Molecular Targets and Cancer Therapeutics
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0302-5
T-DM1 protects against invasive disease
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-018-0164-2
Health burden in cancer survivors: below the tip of the iceberg
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0226-0
Prospective evidence discourages secondary cytoreductive surgery
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0309-y
T cell transfer after allo-HSCT in AML
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0251-z
Paradoxical roles of mutational load as a determinant of anticancer immunity
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0282-5
Combinations provide sustained benefit
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0290-5
New targeted agents for urothelial carcinoma
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0263-8
Rectal cancer — not a waiting game?
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0174-8
TKI-based on/off switch for CAR T cells
来源期刊：Nature Reviews Clinical OncologyDOI：10.1038/s41571-019-0258-5
